Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
Participants will be randomized in a 1:2:2 ratio to receive the double‐blind study treatment (Dimethyl Fumarate, Peginterferon Beta‐1a, and placebo). Participants experiencing a confirmed relapse or disability progression or high lesion burden on MRI will have the option to discontinue the blinded study treatment and switch to an alternative therapy or open‐label BG00012.
Epistemonikos ID: 5126490366b9765947ac32d55c8f0d5b63ce1faf
First added on: Mar 31, 2022